A Phase III randomised comparison of Gemcitabine/Carboplatin with Mitomycin, Ifosfamide and Cisplatin in non-small cell lung cancer

Phase 3

Completed

• Conditions: ung (non-small cell) cancer; Cancer; Malignant neoplasm of bronchus and lung

• Registration Number: ISRCTN52253218
• Lead Sponsor: ondon Lung Cancer Group (UK)

Brief Summary

2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15625369 results

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2001-08-31
• Study Start: 2002-08-19
• Last Update Posted: 8 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 422

Inclusion Criteria

1. Histologically or cytologically proven non-small cell carcinoma of the lung
2. Stage IIIb or IV disease
3. Measurable or evaluable disease
4. Adequate renal function (Ethylene diamine tetraacetic acid [EDTA] Clearance >60 ml/min)
5. Age 18 or over
6. Adequate contraception in females of child-bearing potential
7. Written informed consent
8. No prior radiotherapy or chemotherapy
9. Not less than 8 weeks life expectancy
10. No history of prior malignancy (except non-melanomatous skin tumour or has been without evidence of disease for 3 years or more)
11. White cell count >3000/ml Platelet count >100,000/ml Haemaglobin >10.0 g.dL
12. No symptomatic brain metastases

Exclusion Criteria

Not provided at time of registration

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ot provided at time of registration

Secondary Outcome Measures

Name	Time	Method
ot provided at time of registration